{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:50:24Z","timestamp":1791384624750,"version":"4.3.3"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.imbio.2016.10.008","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T05:11:04Z","timestamp":1476681064000},"page":"164-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: A randomized double-blind and placebo-controlled trial"],"prefix":"10.1016","volume":"222","author":[{"given":"Guoxun","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhui","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianli","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2016.10.008_bib0005","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.1780330811","article-title":"The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imbio.2016.10.008_bib0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.taap.2015.07.007","article-title":"Antioxidant potential of CORM-A1 and resveratrol during TNF-alpha\/cycloheximide-induced oxidative stress and apoptosis in murine intestinal epithelial MODE-K cells","volume":"288","author":"Babu","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.imbio.2016.10.008_bib0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00296-009-1147-5","article-title":"Infliximab therapy in pediatric Takayasu\u2019s arteritis: report of two cases","volume":"31","author":"Buonuomo","year":"2011","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.imbio.2016.10.008_bib0020","first-page":"610","article-title":"Effects of resveratrol on hippocampal astrocytes and expression of TNF-alpha in Alzheimer\u2019s disease model rate","volume":"44","author":"Cheng","year":"2015","journal-title":"Wei Sheng Yan Jiu"},{"key":"10.1016\/j.imbio.2016.10.008_bib0025","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.autrev.2011.11.025","article-title":"Anti TNF-alpha in refractory Takayasu\u2019s arteritis: cases series and review of the literature","volume":"11","author":"Comarmond","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.imbio.2016.10.008_bib0030","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/art.20300","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis","volume":"50","author":"Hoffman","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imbio.2016.10.008_bib0035","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1253\/circj.CJ-12-0131","article-title":"Diagnosis and assessment of Takayasu arteritis by multiple biomarkers","volume":"77","author":"Ishihara","year":"2013","journal-title":"Circ. J."},{"key":"10.1016\/j.imbio.2016.10.008_bib0040","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.3892\/mmr.2016.5057","article-title":"Effects of resveratrol and genistein on nuclear factorkappaB, tumor necrosis factoralpha and matrix metalloproteinase9 in patients with chronic obstructive pulmonary disease","volume":"13","author":"Liu","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.imbio.2016.10.008_bib0045","first-page":"671","article-title":"Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM"},{"key":"10.1016\/j.imbio.2016.10.008_bib0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cbi.2014.12.033","article-title":"Effects of chronic resveratrol supplementation in military firefighters undergo a physical fitness test-a placebo-controlled, double blind study","volume":"227","author":"Macedo","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.imbio.2016.10.008_bib0055","first-page":"63","article-title":"Refractory Takayasu arteritis successfully treated with infliximab","volume":"13","author":"Maffei","year":"2009","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.imbio.2016.10.008_bib0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.rdc.2007.07.014","article-title":"Takayasu arteritis: what is the long-term prognosis?","volume":"33","author":"Maksimowicz-McKinnon","year":"2007","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.imbio.2016.10.008_bib0065","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/art.22404","article-title":"Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients","volume":"56","author":"Maksimowicz-McKinnon","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imbio.2016.10.008_bib0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00005-015-0377-3","article-title":"Inflammaging and anti-inflammaging: the role of cytokines in extreme longevity","volume":"64","author":"Minciullo","year":"2016","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)"},{"key":"10.1016\/j.imbio.2016.10.008_bib0075","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/ard.2008.093260","article-title":"Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up","volume":"67","author":"Molloy","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imbio.2016.10.008_bib0080","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2203\/dose-response.09-015.Mukherjee","article-title":"Dose-dependency of resveratrol in providing health benefits","volume":"8","author":"Mukherjee","year":"2010","journal-title":"Dose Response"},{"key":"10.1016\/j.imbio.2016.10.008_bib0085","first-page":"140","article-title":"Takayasu\u2019s truncoarteritis in Japan. A statistical observation of 76 autopsy cases","volume":"43","author":"Nasu","year":"1975","journal-title":"Pathol. Microbiol. (Basel)"},{"key":"10.1016\/j.imbio.2016.10.008_bib0090","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbacli.2015.04.001","article-title":"Recent advances in the field of anti-cancer immunotherapy","volume":"3","author":"Neves","year":"2015","journal-title":"BBA Clin."},{"key":"10.1016\/j.imbio.2016.10.008_bib0095","first-page":"44","article-title":"Ten-year investigation of clinical, laboratory and radiologic manifestations and complications in patients with Takayasu\u2019s arteritis in three university hospitals","volume":"20","author":"Nooshin","year":"2013","journal-title":"Malays. J. Med. Sci."},{"key":"10.1016\/j.imbio.2016.10.008_bib0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1590\/S0482-50042010000300009","article-title":"Takayasu arteritis: anti-TNF therapy in a Brazilian setting","volume":"50","author":"Nunes","year":"2010","journal-title":"Rev. Bras. Reumatol."},{"key":"10.1016\/j.imbio.2016.10.008_bib0105","doi-asserted-by":"crossref","first-page":"e0147034","DOI":"10.1371\/journal.pone.0147034","article-title":"Resveratrol protects against TNF-alpha-induced injury in human umbilical endothelial cells through promoting sirtuin-1-induced repression of NF-KB and p38 MAPK","volume":"11","author":"Pan","year":"2016","journal-title":"PLoS One"},{"issue":"671","key":"10.1016\/j.imbio.2016.10.008_bib0110","first-page":"e11","article-title":"Intact giant abdominal aortic aneurysm due to Takayasu arteritis","volume":"27","author":"Parameshwarappa","year":"2013","journal-title":"Ann. Vasc. Surg."},{"key":"10.1016\/j.imbio.2016.10.008_bib0115","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/rheumatology\/kei266","article-title":"Serum cytokine profiles and their correlations with disease activity in Takayasu\u2019s arteritis","volume":"45","author":"Park","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.imbio.2016.10.008_bib0120","first-page":"922","article-title":"Long-term efficacy and improvement of health-related quality of life in patients with Takayasu\u2019s arteritis treated with infliximab","volume":"30","author":"Quartuccio","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.imbio.2016.10.008_bib0125","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.arcmed.2015.05.005","article-title":"Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: a randomized, double-Blind, placebo-controlled pilot study","volume":"46","author":"Samsami-Kor","year":"2015","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.imbio.2016.10.008_bib0130","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/acr.21636","article-title":"Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup","volume":"64","author":"Schmidt","year":"2012","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.imbio.2016.10.008_bib0135","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2169\/internalmedicine.45.1377","article-title":"Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate","volume":"45","author":"Tanaka","year":"2006","journal-title":"Intern. Med."},{"key":"10.1016\/j.imbio.2016.10.008_bib0140","first-page":"304","article-title":"Refractory Takayasu\u2019s arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab","volume":"24","author":"Tato","year":"2005","journal-title":"Int. Angiol."},{"key":"10.1016\/j.imbio.2016.10.008_bib0145","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.amjcard.2012.03.030","article-title":"One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease","volume":"110","author":"Tome-Carneiro","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.imbio.2016.10.008_bib0150","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.2174\/13816128113199990407","article-title":"Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence","volume":"19","author":"Tome-Carneiro","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.imbio.2016.10.008_bib0155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.phrs.2013.03.011","article-title":"One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease","volume":"72","author":"Tome-Carneiro","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.imbio.2016.10.008_bib0160","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2005.09.010","article-title":"High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu\u2019s arteritis","volume":"118","author":"Tripathy","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.imbio.2016.10.008_bib0165","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","article-title":"Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab","volume":"34","author":"Wallis","year":"2005","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.imbio.2016.10.008_bib0170","doi-asserted-by":"crossref","DOI":"10.1177\/1535370216637940","article-title":"Resveratrol attenuated TNF-alpha-induced MMP-3 expression in human nucleus pulposus cells by activating autophagy via AMPK\/SIRT1 signaling pathway","author":"Wang","year":"2016","journal-title":"Exp. Biol. Med. (Maywood)"}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298516304156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298516304156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:43:49Z","timestamp":1759250629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298516304156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0171298516304156"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2016.10.008","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: A randomized double-blind and placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2016.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}